A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (NCT06647498)
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Who can join: Review the eligibility criteria below.
Location: University of Alabama in Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- University of Alabama in Birmingham — Birmingham, Alabama
- University of California San Diego Medical Center — La Jolla, California
- University of Southern Califonria — Los Angeles, California
- Yale University School of Medicine — New Haven, Connecticut
- Emory University — Atlanta, Georgia
- Advocate Lutheran General Hospital — Park Ridge, Illinois
- Indiana University School of Medicine — Indianapolis, Indiana
- Washington University in St. Louis — St Louis, Missouri
- New York University Medical Center — New York, New York
- University of Pittsburgh — Pittsburgh, Pennsylvania
- Butler Hospital — Providence, Rhode Island
- Kerwin Research and Memory Center — Dallas, Texas
- University of Washington — Seattle, Washington
- Instituto de Investigaciones Neurologicas Raul Carrea, FLENI — Ciudad Autonoma de Buenos Aire,
- Neuroscience Research Australia — Randwick, New South Wales
- Alzheimer's Research Australia — Melbourne, Victoria
- UBC Hospital — Vancouver, British Columbia
- Sunnybrook Health Sciences Centre — Toronto, Ontario
- McGill Center for Studies in Aging — Verdun, Quebec
- CHU de Quebec - Hôpital de l' Enfant Jésus — Québec,
- Grupo de Neurociencias Sede de la Universidad de Antioquia — Medellín,
- CHU de Toulouse - Hôpital Purpan — Toulouse, Haute Garonne
- Hopital Roger Salengro - CHU Lille — Lille, Nord
- Groupe Hospitalier Pitie-Salpetriere — Paris, Paris
- Hopital Neurologique Pierre Wertheimer — Bron, Rhone
📞 Contact the Study Coordinator
Phone: (844) 342-6397
Email: dianexr@wustl.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimers Disease
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) — Birmingham, Alabama
- Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease — Atlantis, Florida
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 — Birmingham, Alabama
- A Post Authorization Registry Study of Participants Treated With LEQEMBI — Vancouver, British Columbia
- A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Phoenix, Arizona
Explore by condition: All Alzheimers Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.